Skip to main content
I

INVION LIMITED — Investor Relations & Filings

Ticker · IVX ISIN · AU000000IVX4 LEI · 529900JY0HVEQEMSSJ32 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,116 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country AU Australia
Listing ASX IVX

About INVION LIMITED

https://inviongroup.com

Invion Limited is a life sciences company dedicated to the development and commercialization of Photosoft technology, a next-generation Photodynamic Therapy (PDT). The company focuses on utilizing this light-activated treatment platform to target various forms of cancer and infectious diseases. Photosoft technology is derived from natural chlorophyll and is designed to selectively destroy malignant cells while minimizing damage to healthy tissue. Invion's research and development efforts are primarily directed toward oncology applications, including the treatment of skin, lung, and ovarian cancers, as well as addressing global health challenges through the treatment of viral and bacterial infections. The company aims to provide non-invasive or minimally invasive therapeutic alternatives that offer improved patient outcomes and reduced side effects compared to conventional treatment modalities.

Recent filings

Filing Released Lang Actions
Notification of cessation of securities - IVX 5 pages 16.1KB
Regulatory Filings
2026-04-30 English
Appendix 4C and Quarterly Activities Report - March 2026 8 pages 681.4KB
Regulatory Filings
2026-04-29 English
Notice of General Meeting/Proxy Form 157 pages 3.2MB
Proxy Solicitation & Information Statement Classification · 1% confidence The document is the full Notice of General Meeting (including Explanatory Statement and Proxy Form) issued to shareholders to solicit their votes on various resolutions at an upcoming virtual General Meeting. This corresponds exactly to the definition of a Proxy Solicitation & Information Statement (PSI).
2026-04-27 English
Bionnova 2026 Investor Presentation 17 pages 1.5MB
Investor Presentation Classification · 1% confidence The document is an ASX announcement clearly titled “INVESTOR PRESENTATION” and includes the full slide deck content (slides with charts, graphs, technology highlights, clinical data, etc.). It is not merely a brief notice of publication nor a transcript of a call, nor any financial report. Therefore it fits squarely under the “Investor Presentation” category (Code: IP).
2026-04-21 English
Skin Cancer Trial Moves to BCC With More Encouraging Signals 3 pages 437.4KB
Regulatory Filings Classification · 1% confidence The document is an ASX announcement providing a clinical trial update on Invion’s Non-Melanoma Skin Cancer trial. It is a company press release of research progress with safety/efficacy highlights and next steps, not a formal financial or governance report, earnings release, capital update, or any of the other specific filing types. It does not attach an annual or interim report, nor is it a presentation, director dealing, dividend notice, or regulatory proxy. Therefore, it falls under the fallback category of general regulatory announcements (RNS).
2026-04-20 English
Change of Director's Interest Notice - Thian Chew 3 pages 393.1KB
Director's Dealing Classification · 1% confidence The document is an Appendix 3Y “Change of Director’s Interest Notice” filed with the ASX under listing rule 3.19A.2. It details shareholdings and transactions by a company director, clearly matching the definition of an insider trade report (director’s dealings). Therefore it should be classified as Director’s Dealing.
2026-04-19 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.